The Changes of Lipid Metabolism in Advanced Renal Cell Carcinoma Patients Treated with Everolimus: A New Pharmacodynamic Marker?

BACKGROUND: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body m...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:PLoS One
Main Authors: Pantano, Francesco, Santoni, Matteo, Procopio, Giuseppe, Rizzo, Mimma, Iacovelli, Roberto, Porta, Camillo, Conti, Alessandro, Lugini, Antonio, Milella, Michele, Galli, Luca, Ortega, Cinzia, Guida, Francesco Maria, Silletta, Marianna, Schinzari, Giovanni, Verzoni, Elena, Modica, Daniela, Crucitti, Pierfilippo, Rauco, Annamaria, Felici, Alessandra, Ballatore, Valentina, Cascinu, Stefano, Tonini, Giuseppe, Carteni, Giacomo, Russo, Antonio, Santini, Daniele
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2015
Teme:
Research Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4401714/
https://ncbi.nlm.nih.gov/pubmed/25885920
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0120427
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki